Stocks and Investing
Stocks and Investing
Fri, August 5, 2022
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
[ Fri, Aug 05th 2022
] - WOPRAI
Andrew Berens Maintained (AGIO) at Buy with Increased Target to $37 on, Aug 5th, 2022
Andrew Berens of SVB Leerink, Maintained "Agios Pharmaceuticals, Inc." (AGIO) at Buy with Increased Target from $33 to $37 on, Aug 5th, 2022.
Andrew has made no other calls on AGIO in the last 4 months.
There is 1 other peer that has a rating on AGIO. Out of the 1 peers that are also analyzing AGIO, 0 agree with Andrew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Andrew
- Salveen Richter of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $16 on, Tuesday, May 24th, 2022
Contributing Sources